Improving Cervical Cancer Screening and Treatment for Women Living with HIV in Nigeria Using Enhanced Implementation Strategies
Led by University of California, San Diego · Updated on 2026-02-10
2436
Participants Needed
2
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ways to improve cervical cancer screening and treatment among women living with HIV WLHIV in Nigeria, a country with a large population affected by HIV and high rates of cervical cancer deaths. This study compares two sets of strategies to integrate cervical cancer services into existing HIV care programs, aiming to enhance screening, treatment, referral completion, and retention in care. The goal is to improve health outcomes and life expectancy for WLHIV facing both HIV and cervical cancer.
The trial involves two groups receiving different implementation strategies. One group follows Core Implementation Strategies including ongoing consultation, educational meetings, strengthening referral systems, and preparing patients to participate actively. The other group receives these Core strategies plus enhanced approaches like community engagement through the Health Beginning Initiative Model and the use of Smart Cards to support patient involvement. The study uses a cluster randomized design to compare these approaches.
Participants are women living with HIV aged 25 to 64 years. Researchers will monitor how well the cervical cancer screening and treatment services reach patients and how sustainable these services are over time. Outcomes include measuring reach at 12 months after enrollment and sustainment near study completion, along with assessing cervical cancer screening and treatment effectiveness 15 months after treating pre-invasive cancer. The study will track participant progress and service delivery throughout the study period ending in 2027.
CONDITIONS
Brief Title
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
Research Team
G
Gregory Aarons, PhD
E
Echezona Ezeanolue, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Core+ Enhanced Implementation Strategies
Core Implementation Strategies
What it is
All elements of the core strategies, plus additional community engagement using the Health Beginning Initiative Model and Smart Cards to facilitate patient engagement.
A set of implementation strategies used to increase participation and adherence in cervical cancer screening. It includes ongoing consultation, educational meetings, strengthening referral systems, and preparing patients to actively participate.
Role in trial
Examines whether added engagement and technology strategies improve screening implementation beyond the core approach.
Serves as the active comparator in the trial’s randomized design.
Primary use
Aims to further boost screening rates and sustained engagement through community involvement and digital tools.
Designed to improve engagement, referral, and participation for cervical cancer screening among women living with HIV.
How it is given or performed
Delivers core strategies, then adds structured community engagement and uses Smart Cards for patient tracking and support.
Provided through consultation, educational meetings, improved referral systems, and patient preparation in clinical and community settings.
Evidence status
Investigational; results for enhanced strategies in cervical cancer screening for women with HIV are not yet published.
Investigational; results for this intervention in this population are not yet published.
Important limitations
Effectiveness of additional engagement strategies and Smart Cards is not yet established; their adoption may depend on local infrastructure and community participation.
Limited to core strategies only; does not leverage community models or digital engagement tools, which may be important for reaching more participants in resource-limited settings.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 25Years - 64Years
FEMALE
Eligibility Criteria
You may qualify if you...
Women living with HIV
Aged 25 to 64 years
You will not qualify if you...
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - 12 months
Participants receive either Core Implementation Strategies or Core+ Enhanced Implementation Strategies to integrate cervical cancer screening, treatment, and management within HIV programs.
Ongoing consultation and educational meetings with healthcare providers throughout the implementation period
Sustainment Monitoring
Duration - 3 months prior to study completion
Participants are observed to assess the sustainment of the integrated cervical cancer screening and treatment services within HIV programs.
Periodic assessments to monitor program sustainment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Improving HIV Testing in European Hospitals by Introducing Dedicated HIV Teams A Multicenter Study Across Ten Countries
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Evaluation of Sacituzumab Tirumotecan in Combination With Pembrolizumab With or Without Bevacizumab Versus Standard Care
as First-Line Maintenance Treatment for Metastatic Cervical Cancer
Safety and Feasibility Study of PVX7 Immunotherapy for Advanced Cervical Cancer in Women Who Completed Primary Treatment
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Phase I Study of Cardunizumab Combined with Pulsed Low-dose Rate Radiation for Recurrent Lung, Esophageal, and Cervical Cancers
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparative effectiveness of implementation strategies for Accelerating Cervical Cancer Elimination through the integration of Screen-and-treat Services (ACCESS study): protocol for a cluster randomized hybrid type III trial in Nigeria.
Babayemi O Olakunde, Ijeoma U Itanyi, John O Olawepo...